This is clinically relevant given that homozygous deletion of CDKN2A/B is part of the criteria that determine the WHO grade of meningiomas under the most recent WHO Classification of CNS tumors [2]. The gene discussed is CDKN2A; the disease is central nervous system neoplasm.